Search results for "Dose adjustment"

showing 5 items of 5 documents

Worsening of Preexisting Psychiatric Conditions During the COVID-19 Pandemic

2020

Objectives: To ascertain factors associated with worsening of psychiatric conditions during the coronavirus disease 2019 (COVID-19) pandemic. Methods: This study anonymously examined 2,734 psychiatric patients worldwide for worsening of their preexisting psychiatric conditions during the COVID-19 pandemic. An independent clinical investigation of 318 psychiatric patients from United States was used for verification. Results: Valid responses mainly from 12 featured countries indicated self-reported worsening of psychiatric conditions in two-thirds of the patients assessed that was through their significantly higher scores on scales for general psychological disturbance, posttraumatic stress …

COVID-19; psychiatric patients; worsening; depression; post traumatic stress disorder; general psychological disturbancemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)lcsh:RC435-571media_common.quotation_subjectPsychological interventionOptimismDose adjustmentlcsh:Psychiatrygeneral psychological disturbancePandemicMedicineworseningPsychiatryDepression (differential diagnoses)media_commonOriginal ResearchPsychiatrypost traumatic stress disorderbusiness.industrypsychiatric patientsCOVID-19Posttraumatic stressPsychiatry and Mental healthFeelingdepressionbusinessFrontiers in Psychiatry
researchProduct

Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study

2020

Abstract Aims To obtain safety and efficacy data of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in a real-life setting in high cardiovascular (CV) risk patients with heterozygous familial hypercholesterolaemia (HeFH) or very-high low-density lipoprotein cholesterol (LDL-C) levels despite maximally tolerated dose of statin ± other lipid-lowering therapies (MTD ± LLTs). ODYSSEY APPRISE was a prospective, single-arm, Phase 3b open-label (≥12 weeks to ≤ 30 months) European/Canadian study with alirocumab. Methods and results Patients received alirocumab 75 or 150 mg every 2 weeks, with dose adjustment based on physician’s judgment. In total, 994 patients were enrolled …

AdultMalemyalgiaCanadamedicine.medical_specialtyStatinEpidemiologymedicine.drug_class030204 cardiovascular system & hematologyAntibodies Monoclonal HumanizedReal life setting03 medical and health sciences0302 clinical medicineDose adjustmentInternal medicinemedicineHumansIn patientProspective Studies030212 general & internal medicineAdverse effectAgedAlirocumabbusiness.industryIncidence (epidemiology)Middle AgedTreatment OutcomeFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessEuropean Journal of Preventive Cardiology
researchProduct

Pr�vention thromboembolischer Komplikationen in der Unfallchirurgie durch Dosisanpassung von niedermolekularem Heparin anhand TAT- und D-Dimer-Werten

2003

Bei unfallchirurgischen Patienten tritt in bis zu 40% eine tiefe Beinvenenthrombose auf. Das individuelle Risiko kann kaum kalkuliert werden. 518 unfallchirurgische Patienten mit Prophylaxe durch eine tagliche Einzeldosis eines niedermolekularen Heparins (NMH) wurden praoperativ und bis zu 10 Tage postoperativ in einer prospektiven Untersuchung beobachtet. Sie wurden in 2 Gruppen unterteilt: Gruppe I mit Huft- und Oberschenkeloperationen sowie Kniegelenkprothesen und Gruppe II mit Knie- und Unterschenkeloperationen. Bestimmt wurden Thrombin-Antithrombin-Komplex und D-Dimer. Eine 2. Dosis NMH wurde bei Uberschreiten des D-Dimer-Cut-off-Wertes verabreicht. Bei sonographischem Verdacht auf ein…

Gynecologymedicine.medical_specialtymedicine.drug_classbusiness.industryLow doseLow molecular weight heparinSurgeryDose adjustmentD-dimerEmergency MedicinemedicineOrthopedics and Sports MedicineSurgerybusinessNiedermolekulares heparinDer Unfallchirurg
researchProduct

Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung…

2015

8073 Background: Afatinib 40 mg/day (oral) is approved for the treatment of pts with advanced EGFRm+ NSCLC. Dose adjustment is recommended according to pre-defined tolerability criteria. We perform...

Pulmonary and Respiratory MedicineBrachial Plexus NeuritisOncologyCancer Researchmedicine.medical_specialtybusiness.industryAfatinibMedizinnon-small cell lung cancer (NSCLC)HematologyPharmacologymedicine.diseasestomatognathic diseasesTolerabilityOncologyEgfr mutationDose adjustmentInternal medicinemedicineIn patientbusinessmedicine.drug
researchProduct

Patient perspectives on methadone maintenance treatment in the Valencia Region: dose adjustment, participation in dosage regulation, and satisfaction…

2005

Desired adjustment of methadone dose, perceived participation in dosage regulation, and satisfaction with methadone treatment centres were assessed in a sample of opioid-dependent patients from the Valencia Region (eastern Spain). An independent interviewer asked 278 consecutively arriving patients to answer the survey, and 165 (59.4%) completed it. Adjustment of methadone dose was assessed with a -10 to +10 visual analogue scale (VAS-MD); participation in methadone dose regulation, with specific questions; and patient satisfaction, with the Verona Service Satisfaction Scale for methadone treatment (VSSS-MT). The methadone dose (mg/d) prescribed by physicians was (mean+/-S.D.) 68.0+/-30.4. …

AdultMalemedicine.medical_specialtyMethadone maintenanceAdolescentVisual analogue scalemedia_common.quotation_subjectPersonal SatisfactionToxicologyDrug Administration ScheduleHeroinPatient satisfactionDose adjustmentInternal medicinemedicineHumansPharmacology (medical)Patient participationPsychiatrymedia_commonPharmacologybusiness.industryHeroin DependenceAddictionMiddle AgedOpioid-Related DisordersPsychiatry and Mental healthSpainFemaleHealth Services ResearchPatient ParticipationbusinessAttitude to HealthMethadonemedicine.drugMethadoneDrug and alcohol dependence
researchProduct